Aurinia Pharmaceuticals Inc. IKAP.F Stock
Aurinia Pharmaceuticals Inc. Price Chart
Aurinia Pharmaceuticals Inc. IKAP.F Financial and Trading Overview
| Aurinia Pharmaceuticals Inc. stock price | 5.05 EUR |
| Previous Close | 8.99 EUR |
| Open | 8.88 EUR |
| Bid | 8.89 EUR x 85900 |
| Ask | 9.26 EUR x 81100 |
| Day's Range | 8.88 - 8.88 EUR |
| 52 Week Range | 3.43 - 12.05 EUR |
| Volume | 210 EUR |
| Avg. Volume | 131 EUR |
| Market Cap | 1.27B EUR |
| Beta (5Y Monthly) | 1.182746 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.4 EUR |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 28.33 EUR |
IKAP.F Valuation Measures
| Enterprise Value | 948.68M EUR |
| Trailing P/E | N/A |
| Forward P/E | -24 |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 8.651368 |
| Price/Book (mrq) | 3.2527473 |
| Enterprise Value/Revenue | 6.462 |
| Enterprise Value/EBITDA | -9.437 |
Trading Information
Aurinia Pharmaceuticals Inc. Stock Price History
| Beta (5Y Monthly) | 1.182746 |
| 52-Week Change | -1.95% |
| S&P500 52-Week Change | 20.43% |
| 52 Week High | 12.05 EUR |
| 52 Week Low | 3.43 EUR |
| 50-Day Moving Average | 9.68 EUR |
| 200-Day Moving Average | 7.47 EUR |
IKAP.F Share Statistics
| Avg. Volume (3 month) | 131 EUR |
| Avg. Daily Volume (10-Days) | 100 EUR |
| Shares Outstanding | 143.03M |
| Float | 140.04M |
| Short Ratio | N/A |
| % Held by Insiders | 7.07% |
| % Held by Institutions | 38.23% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor | 1:50 |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2022 |
| Most Recent Quarter (mrq) | March 31, 2023 |
| Next Fiscal Year End | December 31, 2023 |
Profitability
| Profit Margin | -65.90% |
| Operating Margin (ttm) | -70.27% |
| Gross Margin | 65.01% |
| EBITDA Margin | -68.47% |
Management Effectiveness
| Return on Assets (ttm) | -13.45% |
| Return on Equity (ttm) | -23.077% |
Income Statement
| Revenue (ttm) | 146.81M EUR |
| Revenue Per Share (ttm) | 1.03 EUR |
| Quarterly Revenue Growth (yoy) | 59.09% |
| Gross Profit (ttm) | 83.38M EUR |
| EBITDA | -100530000 EUR |
| Net Income Avi to Common (ttm) | -96756000 EUR |
| Diluted EPS (ttm) | -0.62 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 360.86M EUR |
| Total Cash Per Share (mrq) | 2.52 EUR |
| Total Debt (mrq) | 7.93M EUR |
| Total Debt/Equity (mrq) | 2.03 EUR |
| Current Ratio (mrq) | 10.076 |
| Book Value Per Share (mrq) | 2.73 |
Cash Flow Statement
| Operating Cash Flow (ttm) | -64453000 EUR |
| Levered Free Cash Flow (ttm) | -22619500 EUR |
Profile of Aurinia Pharmaceuticals Inc.
| Country | Germany |
| State | BC |
| City | Victoria |
| Address | 4464 Markham Street |
| ZIP | V8Z 7X8 |
| Phone | 250 708 4272 |
| Website | https://www.auriniapharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 300 |
Aurinia Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on developing and commercializing therapies to treat various diseases with unmet medical need in the United States. The company also offers LUPKYNIS for the treatment of adult patients with active lupus nephritis. It has a collaboration and license agreement with Otsuka Pharmaceutical Co., Ltd. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.
Q&A For Aurinia Pharmaceuticals Inc. Stock
What is a current IKAP.F stock price?
Aurinia Pharmaceuticals Inc. IKAP.F stock price today per share is 5.05 EUR.
How to purchase Aurinia Pharmaceuticals Inc. stock?
You can buy IKAP.F shares on the Frankfurt exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Aurinia Pharmaceuticals Inc.?
The stock symbol or ticker of Aurinia Pharmaceuticals Inc. is IKAP.F.
Which industry does the Aurinia Pharmaceuticals Inc. company belong to?
The Aurinia Pharmaceuticals Inc. industry is Biotechnology.
How many shares does Aurinia Pharmaceuticals Inc. have in circulation?
The max supply of Aurinia Pharmaceuticals Inc. shares is 145.58M.
What is Aurinia Pharmaceuticals Inc. Price to Earnings Ratio (PE Ratio)?
Aurinia Pharmaceuticals Inc. PE Ratio is now.
What was Aurinia Pharmaceuticals Inc. earnings per share over the trailing 12 months (TTM)?
Aurinia Pharmaceuticals Inc. EPS is -0.4 EUR over the trailing 12 months.
Which sector does the Aurinia Pharmaceuticals Inc. company belong to?
The Aurinia Pharmaceuticals Inc. sector is Healthcare.